Altered protein folding may be the molecular basis of most cases of cystic fibrosis
- PMID: 1385213
- DOI: 10.1016/0014-5793(92)81399-7
Altered protein folding may be the molecular basis of most cases of cystic fibrosis
Abstract
Experiments have demonstrated that the cystic fibrosis transmembrane conductance regulator protein (CFTR), containing the most common cystic fibrosis (CF)-causing mutation (delta F508), reaches the plasma membrane in reduced amounts. Studies of a peptide model of CFTR indicate that the delta F508 mutated region is more sensitive to denaturating conditions. This paper proposes that altered protein folding accounts for these findings, and, thus, most cases of CF. Significantly, the hypothesis makes specific predictions about the effect of stabilizing conditions on mutant CFTR, and, further, suggests a new class of pharmaceuticals that may prove effective in the treatment of this important genetic disease.
Similar articles
-
Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.Cell Stress Chaperones. 1996 Jun;1(2):117-25. doi: 10.1379/1466-1268(1996)001<0117:ccctmp>2.3.co;2. Cell Stress Chaperones. 1996. PMID: 9222597 Free PMC article.
-
Dysfunction of CFTR bearing the delta F508 mutation.J Cell Sci Suppl. 1993;17:235-9. J Cell Sci Suppl. 1993. PMID: 7511616 Review.
-
The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR.Nat Genet. 1993 Apr;3(4):311-6. doi: 10.1038/ng0493-311. Nat Genet. 1993. PMID: 7526932
-
Cystic fibrosis: a disease of altered protein folding.J Bioenerg Biomembr. 1997 Oct;29(5):483-90. doi: 10.1023/a:1022439108101. J Bioenerg Biomembr. 1997. PMID: 9511933 Review.
-
A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.J Clin Invest. 1996 Sep 15;98(6):1304-12. doi: 10.1172/JCI118917. J Clin Invest. 1996. PMID: 8823295 Free PMC article.
Cited by
-
On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.Curr Top Med Chem. 2012;12(22):2504-22. doi: 10.2174/1568026611212220006. Curr Top Med Chem. 2012. PMID: 23339304 Free PMC article. Review.
-
A missense mutation in the sodium phosphate co-transporter Slc34a1 impairs phosphate homeostasis.J Am Soc Nephrol. 2008 Sep;19(9):1753-62. doi: 10.1681/ASN.2007121360. Epub 2008 Jun 11. J Am Soc Nephrol. 2008. PMID: 18550648 Free PMC article.
-
Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease.J Bioenerg Biomembr. 2001 Dec;33(6):513-21. doi: 10.1023/a:1012831322753. J Bioenerg Biomembr. 2001. PMID: 11804193 Review.
-
Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.J Pharmacol Clin Toxicol. 2013 Aug 28;1(1):1007. J Pharmacol Clin Toxicol. 2013. PMID: 24855632 Free PMC article.
-
Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease.J Bioenerg Biomembr. 1997 Oct;29(5):417-27. doi: 10.1023/a:1022402105375. J Bioenerg Biomembr. 1997. PMID: 9511927 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical